AVAHHealthcare · Medical Care FacilitiesThe 11 Wall Street analysts covering Aveanna Healthcare Holdings, Inc. hold a median 12-month price target of $15 — +21.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Aveanna Healthcare Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (99): Analysts have, on balance, been raising their forecasts.
Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVAH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +21.4% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | JP Morgan | Maintains | Neutral | $8.00 → $15 |
| 28 Aug 2026 | Barclays | Maintains | Overweight | — |
| 28 Aug 2026 | Barclays | Maintains | Overweight | $9.50 → $15 |
| 24 Aug 2026 | RBC Capital | Maintains | Outperform | $10 → $16 |
| 24 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 24 Aug 2026 | Truist Securities | Maintains | Hold | $11 → $15 |
| 24 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 14 Aug 2026 | BMO Capital | Maintains | Outperform | $10 → $14 |
| 14 Aug 2026 | BMO Capital | Maintains | Outperform | — |
| 14 Aug 2026 | Raymond James | Maintains | Strong Buy | — |
| 14 Aug 2026 | Raymond James | Maintains | Strong Buy | $13 → $15 |
| 14 Aug 2026 | UBS | Maintains | Neutral | — |
| 14 Aug 2026 | UBS | Maintains | Neutral | $8.00 → $13 |
| 14 July 2026 | Truist Securities | Maintains | Hold | $9.00 → $11 |
| 14 July 2026 | Truist Securities | Maintains | Hold | — |
| 9 July 2026 | Barclays | Maintains | Overweight | $9.00 → $9.50 |
| 9 July 2026 | Barclays | Maintains | Overweight | — |
| 3 June 2026 | RBC Capital | Upgrade | Outperform | — |
| 20 May 2026 | Truist Securities | Maintains | Hold | — |
| 18 May 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVAH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Aveanna Healthcare Holdings, Inc. returned +32.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 67% of US stocks
Cheaper than 10% of US stocks
Cheaper than 27% of US stocks
Higher than 60% of US stocks
Higher than 74% of US stocks
Higher than 38% of US stocks
Higher than 68% of US stocks
Higher than 71% of US stocks
Higher than 98% of US stocks
Higher than 92% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aveanna Healthcare Holdings, Inc. has a market value of $2.7B and an enterprise value of $4.1B.
Revenue in the twelve months to 30 June 2026: $2.6B. The latest quarter grew 13.7% year on year.
Net income over the same four quarters: $274.8M, a 10.6% net margin.
Diluted earnings per share, trailing twelve months: $1.23.
Free cash flow in the twelve months to 30 June 2026: $158.4M.
Trailing P/E: 9.8×; forward P/E: 13.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aveanna Healthcare Holdings, Inc. employs 3,500 people — $744K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aveanna Healthcare Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reported that implied volatility in Aveanna Healthcare stock options is surging, citing recent movements in the options market.
Why it matters — AVAH watchers may find the reported options-market activity relevant when monitoring the stock.
Seeking Alpha says healthcare may combine growth potential from forward earnings with defensive demand amid macroeconomic uncertainty. It cites aging demographics, rising medical demand, and spending growth as support for long-term sector expansion, while noting that select healthcare services and facilities companies show strong growth measures.
Why it matters — AVAH watchers may find the sector-wide discussion relevant because it highlights healthcare services and facilities growth, but the excerpt does not discuss Aveanna specifically.
Zacks Investment Research describes its focus on the Zacks Rank system, which uses earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends. The excerpt does not provide a specific assessment of Aveanna Healthcare stock.
Why it matters — AVAH watchers are given context on Zacks’ screening approach, but no stock-specific conclusion is stated in the excerpt.
Zacks Investment Research says Aveanna has a history of earnings surprises and currently has two key factors that it views as supportive of a likely beat in the next quarterly report.
Why it matters — AVAH watchers may note the article's favorable assessment of the company's earnings surprise history and setup ahead of its next report.
Zacks Research compares the year-to-date performance of Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) against their sector. The article examines how each stock's returns have fared relative to its medical peers so far this year.
Why it matters — This comparison offers AVAH watchers context on how the stock is performing relative to both its direct sector and a comparable medical peer, which helps gauge its standing in the market.
The 11 Wall Street analysts covering Aveanna Healthcare Holdings, Inc. have a median 12-month price target of $15, with estimates ranging from $13 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Aveanna Healthcare Holdings, Inc., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aveanna Healthcare Holdings, Inc. 88 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Aveanna Healthcare Holdings, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (99 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +21.4% from the last close, and Ticker Nerd's factor model ranks Aveanna Healthcare Holdings, Inc. 88 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aveanna Healthcare Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVAH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $16 over the next 12 months.
Aveanna Healthcare Holdings, Inc. returned +32.6% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Aveanna Healthcare Holdings Inc. is a diversified home care company that provides pediatric and adult healthcare services across the United States.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "Implied Volatility Surging for Aveanna Healthcare Stock Options". Zacks Investment Research reported that implied volatility in Aveanna Healthcare stock options is surging, citing recent movements in the options market.
Aveanna Healthcare Holdings Inc. is a diversified home care company that provides pediatric and adult healthcare services across the United States. Aveanna Healthcare Holdings Inc. focuses on care delivered in the home and in community-based settings, serving medically complex and chronically ill patients through private duty nursing, home health, hospice, therapy, rehabilitation, and related support services. The company also offers enteral nutrition and other medical products for patients with specialized care needs. Its services are organized across Private Duty Services, Home Health & Hospice, and Medical Solutions, allowing it to address a broad range of clinical and non-clinical needs for newborns, children, adults, and seniors. Headquartered in Atlanta, Georgia, Aveanna Healthcare Holdings Inc. plays a significant role in the U.S. healthcare services market by helping patients receive coordinated care outside traditional institutional settings.
CEO Mr. Jeffrey S. Shaner · 3,500 employees · United States · https://www.aveanna.com
